Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Rudolf A. Baumgartner"'
Autor:
Randall Stoltz, Alan M. Laties, Vernon Humbert, Rudolf A. Baumgartner, Cadmus C Rich, Mcvicar William K, Chaim Brickman
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Purpose: To investigate the safety, tolerability, and pharmacokinetics of trabodenoson, a highly selective adenosine mimetic targeting the adenosine A1 receptor. Methods: In Part 1, 60 healthy adult volunteers were randomized to 14 days of twice-dail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57afd9b6611e390b6e010045e04cfa27
https://doi.org/10.1089/jop.2015.0147
https://doi.org/10.1089/jop.2015.0147
Autor:
Jenni J. Hakkarainen, Giedrius Kalesnykas, David S Albers, Rudolf A. Baumgartner, Cadmus C Rich, Simon Kaja, Symantas Ragauskas, Agne Žiniauskaite
Publikováno v:
Investigative ophthalmologyvisual science. 59(7)
Purpose To determine the efficacy of trabodenoson, an adenosine mimetic with highly selective adenosine A1 receptor binding properties, in a preclinical mouse model for dry-eye disease. Methods Dry-eye disease was induced in adult male C57BL/6 mice u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6d0c4092e722758251eae500bda6609
https://pubmed.ncbi.nlm.nih.gov/30025146
https://pubmed.ncbi.nlm.nih.gov/30025146
Autor:
Yan Guo, Rudolf A. Baumgartner, Steven L. Bernstein, David S Albers, Cadmus C Rich, Mary A. Johnson, Zara Mehrabian
Publikováno v:
Translational Vision Science & Technology
Purpose Nonarteritic anterior ischemic optic neuropathy (NAION) is the leading cause of sudden optic nerve–related vision loss currently without effective treatment. We evaluated the neuroprotective potential of ocular (topical) delivery of trabode
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb634575364099a5b2b8bf678af5869
https://doi.org/10.1167/tvst.8.6.47
https://doi.org/10.1167/tvst.8.6.47
Autor:
Cadmus C Rich, Mcvicar William K, Kenneth N Sall, Rudolf A. Baumgartner, Harvey Dubiner, Natanya Slomowitz, Jonathan S. Myers
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Purpose: To evaluate the safety and ocular hypotensive efficacy of 4 trabodenoson doses administered twice daily over 14 or 28 days in subjects with ocular hypertension or primary open-angle glaucoma (POAG). Methods: In this multicenter, randomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501dfbed3a67c181fe65e293b82c2c10
https://pubmed.ncbi.nlm.nih.gov/27002298
https://pubmed.ncbi.nlm.nih.gov/27002298
Autor:
Rudolf A. Baumgartner, Joel Morganroth, John P. Hanrahan, Amy Wilson, Peter Zimetbaum, Hailong Cheng, Donna R. Grogan
Publikováno v:
Medicine. 87:319-328
Beta-adrenergic stimulation may increase heart rate and the potential for cardiac arrhythmias. The effect of inhaled long-acting beta2-agonists (LABAs) on these outcomes was evaluated in patients with chronic obstructive pulmonary disease (COPD) in 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6e5d78f0a65b8c338419585949e3d9
https://doi.org/10.1097/md.0b013e31818fcc02
https://doi.org/10.1097/md.0b013e31818fcc02
Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma
Autor:
Daniel L. Hamilos, Anthony D'Urzo, Rudolf A. Baumgartner, Mcvicar William K, Kenneth Tripp, Merdad V. Parsey, Robin J. Levy, Michael Marcus
Publikováno v:
Annals of Allergy, Asthma & Immunology. 99:540-548
Previous studies have raised concerns regarding the safety of regular use of beta2-agonists for treating asthma. Few studies have explored the safety of at least 1 year of use of racemic albuterol, and none have examined long-term dosing of levalbute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f51eb9e3a703594d8fdb44c59c31fd35
https://doi.org/10.1016/s1081-1206(10)60384-5
https://doi.org/10.1016/s1081-1206(10)60384-5
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 20:534-542
Objective To characterize the population pharmacokinetics (PK) of (R)- and (S)-albuterol in pediatric asthmatics using a model that supports a sparse blood sampling strategy. Methods The data for this analysis were collected from patients enrolled in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85dc66a8d55138e80970bed02591bdc7
https://doi.org/10.1016/j.pupt.2006.05.003
https://doi.org/10.1016/j.pupt.2006.05.003
Autor:
Rudolf A. Baumgartner, John P. Hanrahan, William J. Calhoun, Kenneth Sciarappa, Nicola A. Hanania, Steven A. Sahn
Publikováno v:
Clinical Therapeutics. 29:261-278
The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa0548c8da47c3608427f871d89e878e
https://doi.org/10.1016/j.clinthera.2007.02.009
https://doi.org/10.1016/j.clinthera.2007.02.009
Autor:
Kenneth Tripp, Merdad V. Parsey, Rudolf A. Baumgartner, Henry Milgrom, David P. Skoner, William E. Berger
Publikováno v:
Current Medical Research and Opinion. 22:1217-1226
To evaluate the efficacy and safety of levalbuterol metered dose inhaler (MDI) in children aged 4-11 years (n = 173).Multicenter, randomized, double-blind 28-day study of QID levalbuterol 90 microg, racemic albuterol 180 mug, and placebo (2:1:1 ratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd11c5f954a4e56749d6ba9576233b74
https://doi.org/10.1185/030079906x112534
https://doi.org/10.1185/030079906x112534
Autor:
Rudolf A. Baumgartner, John P. Hanrahan, Nicola A. Hanania, Charles L. Emerman, Raymond Claus, Kendyl Schaefer, Richard Nowak, Merdad V. Parsey
Publikováno v:
The American Journal of Emergency Medicine. 24:259-267
This multicenter, randomized, double-blind trial compared nebulized levalbuterol (Lev) and racemic albuterol (Rac) in the treatment of acute asthma. Methods Adults with acute asthma exacerbations (FEV 1 20%-55% predicted) received prednisone and eith
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f8a7b4b2690b4a07cc29b9e193008d
https://doi.org/10.1016/j.ajem.2006.01.027
https://doi.org/10.1016/j.ajem.2006.01.027